3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
8
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
4
Endometrial Neoplasms
3
Thyroid Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Interventions
lenvatinib
1
camrelizumab
1
apatinib
1
Cyclophosphamide
1
Albumin-Bound Paclitaxel
1
ALT-803
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Triple Negative Breast Cancer
×
lenvatinib
×
Breast
×
Clear all
NCT06849492
2025-02-27
SHIFT-001
Fudan University
Phase 2
Not yet recruiting
120 enrolled